For the millions who live with diabetes, each day is marked by small rituals of pain — the finger prick, the test strip, the reading, repeated without end. Now, rumors surrounding the Apple Watch 7 suggest that technology may be approaching a threshold where that burden could be lifted, replaced by a sensor worn on the wrist that reads blood sugar continuously, without ever breaking the skin. Whether through terahertz spectroscopy or some adjacent innovation, Apple appears to be pursuing a vision in which the boundary between consumer device and medical instrument quietly dissolves. The promis
BGR
· Feb 13, 2021
· technology
· 3 min read
Medium
Sourcing: Characterized
Apple Watch 7 may use terahertz spectroscopy for non-invasive blood glucose monitoring
Millions of people with diabetes currently endure multiple daily finger pricks for blood glucose monitoring, creating a significant quality-of-life burden.
◉
Health & Medicine
8412 related articles
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% match
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% match
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% match
Related Coverage
BBC News · Aug 25
School asbestos exposure linked to woman's death at 46, family claims
A woman died from mesothelioma at 46, likely exposed to asbestos at her Cardiff school decades earlier. Her family is su…
Future of Personal Health - · Aug 25 NGS Technology Transforms Uncertain Infections Into Actionable DiagnosesHybrid-capture NGS technology helps clinicians identify pathogens in diagnostically challenging cases by simultaneously …
The Guardian · Aug 25 Shark attack survivor Leah Stewart recalls 'monster' in first interview since losing armLeah Stewart, who lost her arm in a June shark attack at Coogee Beach, recalls the traumatic encounter in her first inte…
Education News Canada · Aug 25 Systemic racism, restrictive policies block Black Canadians from blood donationBlack Canadians face systemic barriers to blood donation despite critical need for ethnicity-matched blood for sickle ce…
Bias & Framing
⚖
Article uses promotional framing and speculative language to present unconfirmed Apple Watch 7 features as significant medical advances, with minimal critical perspective on feasibility or limitations.
Bias Direction
center-right
Confidence
HIGH
Promotional/aspirational framing that emphasizes Apple's positive health achievements and positions the rumored glucose sensor as a major breakthrough, while presenting speculative patent findings as substantive evidence.
easily its most exciting attraction
often credited with having saved a wearer's life
even more exciting health monitoring technology
millions of people worldwide have been asking for
perpetual glucose monitoring
feature not available elsewhere
Skepticism about terahertz spectroscopy feasibility for wearables
Regulatory/FDA approval challenges for medical devices
Competing glucose monitoring technologies and their limitations
Cost implications and accessibility concerns
Expert medical opinions on accuracy and reliability claims
Historical context of failed Apple health feature rollouts
Privacy concerns with continuous biometric monitoring
Geopolitical Impact
🌎
Apple's potential blood glucose monitoring technology in wearables is a consumer health innovation with minimal direct geopolitical implications.
Escalation Risk
low
Confidence
LOW
No significant shifts. This is a commercial technology development by a U.S. company that may influence global medical device markets and healthcare accessibility standards.
Economic Lens
📈
Apple Watch 7's rumored non-invasive blood glucose sensor using terahertz spectroscopy could disrupt the diabetes monitoring market, potentially reducing demand for traditional glucose meters and continuous glucose monitors while creating new healthcare technology opportunities.
Market Signal
mixed
Confidence
MED
Medical devices and diagnostics
Diabetes care products
Consumer electronics/wearables
Healthcare services
Pharmaceutical distribution
Health insurance
Diabetic patients could benefit from reduced testing costs, improved convenience, and better health outcomes through continuous monitoring. However, initial adoption may be limited by Apple Watch price ($300+) and potential accuracy concerns. Could reduce out-of-pocket expenses for frequent glucose test strips.
FDA regulatory approval required for medical-grade accuracy claims; potential reimbursement discussions with insurers; possible disruption to existing glucose monitor manufacturers' market share; data privacy regulations around continuous health monitoring; potential antitrust scrutiny of Apple's healthcare ecosystem expansion.